A Phase 2 interventional study of MK-6916 and Hydrocodone/acetaminophen (HB/APAP) in Pain Management, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines. Researchers designed a trial medicine called MK-6916 to treat pain.
The goal of the trial is to learn if at least 1 dose of MK-6916 works better than placebo to lessen pain. A placebo looks like the trial medicine but has no trial medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MK-6916 120 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Drug: MK-6916 · Drug: Rescue Medication
Participants will receive MK-6916 70 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Drug: MK-6916 · Drug: Rescue Medication
Participants will receive hydrocodone 5 mg/acetaminophen 325 mg (HB/APAP) every 6 hours (q6h) for 48 hours. Participants may receive rescue medication q6h. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Drug: Hydrocodone/acetaminophen (HB/APAP) · Drug: Rescue Medication
Participants will receive MK-6916 placebo every 6 hours (q6h). Participants may receive rescue medication q6h for 48 hours. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Drug: MK-6916 Placebo · Drug: Rescue Medication
120 mg or 70 mg oral tablet given every 12 hours (q12h) for 48 hours.
Hydrocodone 5 mg/acetaminophen 325 mg given as oral capsule every 6 hours (q6h) for 48 hours.
Placebo oral table given every 6 hours (q6h) for 48 hours
Participants requesting rescue medication may receive protocol-specified rescue medication. Rescue treatment consists of open-label oxycodone immediate release (IR) oral tablet 5 mg given every 6 hours (q6h) (given in 5 mg increments for a maximum dose of 10 mg q6h). Participants should be encouraged to wait 1 hour after administration of the first dose of oxycodone 5 mg before administering a second dose. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.
Sum of the Pain Intensity Difference 0 to 48 Hours (SPID48)
The Sum of the Pain Intensity Difference (SPID) scale quantifies cumulative pain reduction to measure how effectively a pain medication or treatment works over a specific period of time. Pain is assessed by the participant using the Numeric Pain Rating Scale (NPRS) Brief Pain Inventory-Short Form (BPI-SF) "Pain Now" Item, which is a single item questionnaire asking the participant to rate their "pain now" using the numeric rating scale (0= No pain; 10= pain as bad as you can imagine; a higher score indicates more pain). The current pain score is subtracted from the baseline score at regular intervals at which pain is assessed to find the "Pain Intensity Difference". These differences are multiplied by the time interval and added together to yield the SPID. A higher SPID score indicates that a participant experienced more significant, cumulative pain relief during the study window. The least squares (LS) means and standard error will be provided for each treatment group.
Time frame: Up to approximately 48 hours
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.
Time frame: Up to approximately 16 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.
Time frame: Up to approximately 48 hours
Time to ≥2-Point Improvement on the Numeric Pain Rating Scale (NPRS) Brief Pain Inventory-Short Form (BPI-SF) "Pain Now" Single Item Questionnaire
The NPRS BPI-SF "Pain Now" Item is a single item questionnaire asking the participant to rate their "pain now" using the numeric rating scale (0= No pain; 10= pain as bad as you can imagine; a higer score indicates more pain). Pain is assessed by the participant using the NPRS BPI-SF "Pain Now" Item. Participants are assessed at baseline, and before each dose of study intervention and rescue medication. The time to ≥2-point improvement on the NPRS BPI-SF "Pain Now" Item is defined as the time, in minutes, from baseline to the time to ≥2 point reduction in pain intensity as measured by the NPRS BPI-SF "Pain Now" single item questionnaire, as estimated by the Kaplan-Meier method for each treatment group.
Time frame: Baseline and up to approximately 48 hours
Total Amount of Opioid Rescue Medication Used (mg) from 0 to 48 Hours
The total amount of opioid rescue medications used from 0 to 48 hours will be expressed as total milligrams (mg) of opioid rescue medications administered from 0 to 48 hours. Per protocol, the stratified Wilcoxon rank-sum test, stratified by baseline NPRS, will be performed to compare MK-6916 and placebo.
Time frame: Up to approximately 48 hours
Percentage of Participants who used any Opioid Rescue Medications from 0 to 48 hours
The percentage of participants who used any opioid rescue medication will be compared between MK-6916 and placebo, using the stratified Miettinen and Nurminen method, with baseline NPRS as the stratification factor.
Time frame: Up to approximately 48 hours
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Start is estimated for Nov 2026; primary completion for Jun 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6916
Agnosia